EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications

Qinghua Xie, Hongyan Zhao, Xuan Yang, Hongqi Zhang, Hong Liu, Jinghua Pan, Yan Li, Danping Fan, Xinrong Fan

Frontiers in Immunology · 2026

DOI: 10.3389/fimmu.2026.1685015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Qinghua Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Adenosine, Prostatic Neoplasms, Prostatic Hyperplasia, Prostatic Diseases. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-related diseases, including prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa), represent significant threats to the health of the aging male population worldwide. Despite their prevalence, the pathogenesis of prostate-related diseases has not been elucidated. Recent studies have shown that N 6 -methyladenosine (m 6 A) modification is widely involved in the progression of prostate-related diseases. In this review, we summarized recent advances in understanding the core m 6 A regulatory machinery comprising writers such as the methyltransferase-like 3 (METTL3)-METTL14 complex, erasers including fat mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKBH5), and readers, including the YTH domain-containing family proteins (YTHDFs), YTHDC proteins, insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs), and heterogeneous nuclear ribonucleoproteins (HNRNPs). Specifically, we elucidated how dysregulation of these components drives disease progression via alterations in cellular proliferation, differentiation, inflammatory responses, and stem cell dynamics. Notably, m 6 A modifications help shape the immunosuppressive landscape in PCa by modulating immune checkpoint expression, cytokine networks, and immune cell infiltration, thereby critically influencing therapeutic responses to immunotherapy. Furthermore, this review highlights the emerging diagnostic potential and therapeutic viability of m 6 A-targeted strategies, offering valuable insights for future clinical translation in prostate-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosineProstatic NeoplasmsProstatic HyperplasiaProstatic DiseasesHumansMaleRNA MethylationEpitranscriptomeAnimalsMethyltransferases

Stichwörter der Autor:innen

benign prostatic hyperplasiam6A methylation modificationprostate cancerprostate-related diseasesprostatitis

Substanzen

AdenosineN-methyladenosineMethyltransferases

Autor:innen und Institutionen

  • Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xie, Q., Zhao, H., Yang, X., Zhang, H., Liu, H., Pan, J., Li, Y., Fan, D., & Fan, X. (2026). The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1685015

Vancouver

Xie Q, Zhao H, Yang X, Zhang H, Liu H, Pan J, et al. The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1685015

BibTeX
@article{Xie2026,
  author = {Xie, Qinghua and Zhao, Hongyan and Yang, Xuan and Zhang, Hongqi and Liu, Hong and Pan, Jinghua and Li, Yan and Fan, Danping and Fan, Xinrong},
  title = {The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications},
  journal = {Frontiers in Immunology},
  year = {2026},
  doi = {10.3389/fimmu.2026.1685015}
}
Kostenlos starten →